There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
In this issue of Blood, Sugata et al report that vaccination against human T-cell
leukemia virus type 1 (HTLV-1) basic leucine zipper (bZIP) factor (HBZ) could be used
for immunotherapy in adult T-cell leukemia-lymphoma (ATL) patients.